Skip to main content

TGF-beta Archives

Symposium honors Moses’ storied cancer research career

Oct. 19, 2017—Members of the Vanderbilt University Medical Center (VUMC) community and others whose lives and careers have been influenced by legendary cancer investigator, educator and administrator Harold (Hal) Moses, M.D., have endowed the Linda and Harold L. Moses, M.D. Career Development Fund.

Read more


Colorectal cancer clues

Jan. 19, 2017—Although cancers arising from different areas of the large intestine are heterogeneous, they appear to use similar important tumorigenic pathways.

Read more


Surprising finding in the kidney

Apr. 16, 2015—TGF-beta signaling in the kidney was thought to be a target for reducing renal fibrosis, but Vanderbilt researchers report that fibrosis still occurs in the absence of TGF-beta signaling.

Read more


Enzyme affects tumor metastasis

Jan. 8, 2015—A protein that degrades the “matrix” between cells participates in the development of lung metastases from primary breast cancer in mouse models and may be a good target for breast cancer treatment.

Read more


New insight on oral cancer culprits

Nov. 12, 2014—A new mouse model offers insight into the signaling pathways that control oral cancers – and a platform for testing anticancer therapeutics.

Read more


Molecular ‘chat’ holds kidney fibrosis clues

Jul. 10, 2014—A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process.

Read more


Preventing hardened heart valves

Dec. 26, 2012—Blocking a serotonin receptor may provide a novel therapy for heart valve disease.

Read more


Proteins guard against cancer spread

Jul. 24, 2012—Targeting immune system proteins may keep prostate cancer from spreading to bone.

Read more


Smoking stokes cells’ cancer capacity

Mar. 23, 2012—Cellular pathways altered by chronic exposure to cigarette smoke may reveal new biomarkers to assess smoking-induced lung cancer risk.

Read more


Colon cancer’s cellular crossroads

Mar. 16, 2012—New information about signaling pathways involved in colorectal cancer could aid in assessing prognosis and identifying new therapeutic targets for the disease.

Read more


Drugs reverse lung cancer cell changes

Feb. 1, 2012—Drugs that target “epigenetic” changes may help treat or slow the progression of lung cancer.

Read more